Recent treatment advances and practical management of hepatitis D virus.
Hepatitis D virus
bulevirtide
lonafarnib
nucleic acid polymer REP 2139
pegylated interferon
Journal
Clinical medicine (London, England)
ISSN: 1473-4893
Titre abrégé: Clin Med (Lond)
Pays: England
ID NLM: 101092853
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
medline:
14
4
2024
pubmed:
14
4
2024
entrez:
13
4
2024
Statut:
ppublish
Résumé
Hepatitis D virus (HDV), also referred to as hepatitis delta virus, is the smallest virus capable of causing human disease. It is unable to replicate on its own and can only propagate in the presence of hepatitis B virus (HBV). Infection with both HBV and HDV frequently results in more severe disease than HBV alone, with higher instances of cirrhosis, liver failure and hepatocellular carcinoma (HCC). Thus, there is a need for effective treatment for HDV; however, currently approved treatment options are very limited both in terms of their efficacy and availability. This makes the management of HDV a challenge for physicians. In this review, we look at the background, diagnosis and treatment of HDV, informed by our hospital data, to set out the optimal management of HDV; we also explore novel treatment options for this disease.
Identifiants
pubmed: 38614656
pii: S1470-2118(24)04589-5
doi: 10.7861/clinmed.2022-0556
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
403-408Informations de copyright
Copyright © 2023 © 2023 THE AUTHORS. Published by Elsevier Limited on behalf of the Royal College of Physicians. Published by Elsevier Ltd.. All rights reserved.